NVCR
NovoCure Limited
Price Chart
Latest Quote
$13.98
+0.37 (+2.72%)
Current Price
| Previous Close | $13.61 |
| Open | $13.43 |
| Day High | $14.24 |
| Day Low | $13.43 |
| Volume | 914,139 |
Stock Information
| Shares Outstanding | 115.82M |
| Total Debt | $234.94M |
| Cash Equivalents | $432.00M |
| Revenue | $674.41M |
| Net Income | $-173.05M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $1.62B |
| EPS (TTM) | $-1.53 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.38B |
| Sales | $674.41M |
| Income | $-173.05M |
| Book/sh | $2.85 |
| Cash/sh | $3.73 |
| Employees | 2K |
Financial Ratios
| Quick Ratio | 2.66 |
| Current Ratio | 2.90 |
| Debt/Eq | 71.04 |
Returns & Margins
| ROA | -11.06% |
| ROE | -49.96% |
| Gross Margin | 75.45% |
| Operating Margin | -38.73% |
| Profit Margin | -25.66% |
Ownership
| Insider Ownership | 10.01% |
| Institutional Ownership | 88.35% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -11.72 |
| P/S | 2.40 |
| P/B | 4.90 |
Analyst Data
| Recommendation | buy |
| Target Price | $26.00 |
Technical Indicators
| SMA20 | $16.71 |
| SMA50 | $15.75 |
| SMA200 | $13.37 |
| RSI | 41.39 |
| ATR | 1.2308 |
| Shares Float | 95.25M |
| Short Float | 10.70% |
| Short Ratio | 4.66 |
| Volatility | 0.92 |
| Rel Volume | 0.54 |
Performance History
| Week | -20.57% |
| Month | -21.90% |
| Quarter | +18.27% |
| 6 Months | +11.31% |
| YTD | +6.55% |
| Year | -16.24% |
| 3 Years | -68.15% |
| 5 Years | -93.55% |
| 10 Years | +27.55% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $13.98 | 914,139 |
| 2026-06-22 | $13.61 | 1,955,800 |
| 2026-06-18 | $14.28 | 4,850,200 |
| 2026-06-17 | $17.85 | 1,308,900 |
| 2026-06-16 | $17.49 | 1,022,500 |
| 2026-06-15 | $17.60 | 2,767,800 |
| 2026-06-12 | $17.78 | 1,037,300 |
| 2026-06-11 | $17.71 | 1,347,900 |
| 2026-06-10 | $16.65 | 982,100 |
| 2026-06-09 | $17.24 | 1,544,000 |
| 2026-06-08 | $16.85 | 1,178,600 |
| 2026-06-05 | $17.16 | 2,168,000 |
| 2026-06-04 | $17.99 | 2,251,200 |
| 2026-06-03 | $16.15 | 1,696,000 |
| 2026-06-02 | $15.82 | 1,390,100 |
| 2026-06-01 | $16.56 | 1,603,600 |
| 2026-05-29 | $17.04 | 1,339,100 |
| 2026-05-28 | $17.25 | 1,211,100 |
| 2026-05-27 | $16.99 | 1,481,600 |
| 2026-05-26 | $18.26 | 1,929,400 |
About NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
đ° Latest News
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?
Motley Fool âĸ 2026-06-22T14:59:30Z
NovoCure (NVCR) Stock Could Be 45.2% Below Fair Value After TRIDENT Trial Miss
Simply Wall St. âĸ 2026-06-20T20:07:57Z
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?
Motley Fool âĸ 2026-06-19T17:10:34Z
Novocure Tumbles After Cancer-Fighting Medical Device Flops In Brain Cancer
Investor's Business Daily âĸ 2026-06-18T20:05:42Z
Top Midday Decliners
MT Newswires âĸ 2026-06-18T18:03:21ZSector Update: Healthcare Stocks Decline Thursday Afternoon
MT Newswires âĸ 2026-06-18T17:34:58ZNovocureâs Optune Gio fails to show benefit at earlier stage
Medical Device Network âĸ 2026-06-18T16:04:28Z
Stocks Supported as Geopolitical Risks Recede
Barchart âĸ 2026-06-18T15:17:09Z
Novocure Shares Slide After Phase 3 Glioblastoma Study Falls Short of Survival Goal
InvestorsHub âĸ 2026-06-18T12:53:49Z
FreeCast surges premarket; Accenture, Novocure slide
Investing.com âĸ 2026-06-18T12:22:43Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $166,879,000 | $137,181,000 | $128,280,000 | $114,867,000 |
| Cost Of Revenue | $166,879,000 | $137,181,000 | $128,280,000 | $114,867,000 |
| Total Revenue | $655,353,000 | $605,220,000 | $509,338,000 | $537,840,000 |
| Operating Revenue | $655,353,000 | $605,220,000 | $509,338,000 | $537,840,000 |
| Expenses | ||||
| Interest Expense | $17,037,000 | $10,343,000 | $3,319,000 | $3,334,000 |
| Total Expenses | $809,153,000 | $775,716,000 | $742,208,000 | $627,363,000 |
| Other Income Expense | $-4,322,000 | $-717,000 | $-797,000 | $-3,523,000 |
| Net Non Operating Interest Income Expense | $21,872,000 | $40,051,000 | $41,927,000 | $11,200,000 |
| Total Other Finance Cost | $-26,035,000 | $-27,670,000 | $-25,607,000 | $-3,573,000 |
| Interest Expense Non Operating | $17,037,000 | $10,343,000 | $3,319,000 | $3,334,000 |
| Operating Expense | $642,274,000 | $638,535,000 | $613,928,000 | $512,496,000 |
| Selling And Marketing Expense | $240,064,000 | $239,063,000 | $226,809,000 | $173,658,000 |
| General And Administrative Expense | $177,666,000 | $189,827,000 | $164,057,000 | $132,753,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-136,227,000 | $-168,627,000 | $-207,043,000 | $-92,534,000 |
| Net Interest Income | $21,872,000 | $40,051,000 | $41,927,000 | $11,200,000 |
| Interest Income | $12,874,000 | $22,724,000 | $19,639,000 | $10,961,000 |
| Normalized Income | $-131,905,864 | $-168,060,570 | $-206,413,370 | $-89,750,830 |
| Net Income From Continuing And Discontinued Operation | $-136,227,000 | $-168,627,000 | $-207,043,000 | $-92,534,000 |
| Total Operating Income As Reported | $-153,800,000 | $-170,496,000 | $-232,870,000 | $-89,523,000 |
| Net Income Common Stockholders | $-136,227,000 | $-168,627,000 | $-207,043,000 | $-92,534,000 |
| Net Income | $-136,227,000 | $-168,627,000 | $-207,043,000 | $-92,534,000 |
| Net Income Including Noncontrolling Interests | $-136,227,000 | $-168,627,000 | $-207,043,000 | $-92,534,000 |
| Net Income Continuous Operations | $-136,227,000 | $-168,627,000 | $-207,043,000 | $-92,534,000 |
| Pretax Income | $-136,250,000 | $-131,162,000 | $-191,740,000 | $-81,846,000 |
| Interest Income Non Operating | $12,874,000 | $22,724,000 | $19,639,000 | $10,961,000 |
| Operating Income | $-153,800,000 | $-170,496,000 | $-232,870,000 | $-89,523,000 |
| Gross Profit | $488,474,000 | $468,039,000 | $381,058,000 | $422,973,000 |
| Per Share | ||||
| Diluted EPS | $-1.22 | $-1.56 | $-1.95 | $-0.88 |
| Basic EPS | $-1.22 | $-1.56 | $-1.95 | $-0.88 |
| Other | ||||
| Tax Effect Of Unusual Items | $-864 | $-150,570 | $-167,370 | $-739,830 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-100,241,000 | $-108,867,000 | $-176,655,000 | $-64,365,000 |
| Total Unusual Items | $-4,322,000 | $-717,000 | $-797,000 | $-3,523,000 |
| Total Unusual Items Excluding Goodwill | $-4,322,000 | $-717,000 | $-797,000 | $-3,523,000 |
| Reconciled Depreciation | $14,650,000 | $11,235,000 | $10,969,000 | $10,624,000 |
| EBITDA (Bullshit earnings) | $-104,563,000 | $-109,584,000 | $-177,452,000 | $-67,888,000 |
| EBIT | $-119,213,000 | $-120,819,000 | $-188,421,000 | $-78,512,000 |
| Diluted Average Shares | $111,471,991 | $107,834,368 | $106,391,178 | $104,660,476 |
| Basic Average Shares | $111,471,991 | $107,834,368 | $106,391,178 | $104,660,476 |
| Diluted NI Availto Com Stockholders | $-136,227,000 | $-168,627,000 | $-207,043,000 | $-92,534,000 |
| Tax Provision | $-23,000 | $37,465,000 | $15,303,000 | $10,688,000 |
| Gain On Sale Of Security | $-4,322,000 | $-717,000 | $-797,000 | $-3,523,000 |
| Research And Development | $224,544,000 | $209,645,000 | $223,062,000 | $206,085,000 |
| Selling General And Administration | $417,730,000 | $428,890,000 | $390,866,000 | $306,411,000 |
| Other Gand A | $177,666,000 | $189,827,000 | $164,057,000 | $132,753,000 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $340,466,000 | $360,179,000 | $362,496,000 | $441,170,000 |
| Total Assets | $804,326,000 | $1,240,784,000 | $1,146,129,000 | $1,191,648,000 |
| Total Non Current Assets | $157,595,000 | $134,209,000 | $111,720,000 | $80,119,000 |
| Other Non Current Assets | $10,596,000 | $14,618,000 | $14,022,000 | $11,161,000 |
| Current Assets | $646,731,000 | $1,106,575,000 | $1,034,409,000 | $1,111,529,000 |
| Restricted Cash | $9,842,000 | $2,327,000 | $1,743,000 | $508,000 |
| Prepaid Assets | $9,657,000 | $7,217,000 | $6,784,000 | $6,195,000 |
| Inventory | $41,111,000 | $35,086,000 | $38,152,000 | $29,376,000 |
| Receivables | $138,447,000 | $102,072,000 | $77,114,000 | $106,025,000 |
| Other Receivables | $49,012,000 | $27,846,000 | $15,893,000 | $19,764,000 |
| Accounts Receivable | $89,435,000 | $74,226,000 | $61,221,000 | $86,261,000 |
| Cash Cash Equivalents And Short Term Investments | $447,674,000 | $959,873,000 | $910,616,000 | $969,425,000 |
| Cash And Cash Equivalents | $93,548,000 | $163,767,000 | $240,821,000 | $115,326,000 |
| Cash Equivalents | $86,146,000 | $151,919,000 | $230,866,000 | $105,629,000 |
| Cash Financial | $7,402,000 | $11,848,000 | $9,955,000 | $9,697,000 |
| Debt | ||||
| Net Debt | $101,499,000 | $491,693,000 | $328,001,000 | $450,183,000 |
| Total Debt | $248,353,000 | $683,340,000 | $604,564,000 | $584,271,000 |
| Long Term Debt And Capital Lease Obligation | $236,694,000 | $117,271,000 | $596,242,000 | $584,271,000 |
| Long Term Debt | $195,047,000 | $97,300,000 | $568,822,000 | $565,509,000 |
| Current Debt And Capital Lease Obligation | $11,659,000 | $566,069,000 | $8,322,000 | - |
| Current Debt | - | $558,160,000 | - | - |
| Other Current Borrowings | - | $558,160,000 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $463,860,000 | $880,605,000 | $783,633,000 | $750,478,000 |
| Total Non Current Liabilities Net Minority Interest | $240,632,000 | $124,211,000 | $604,518,000 | $591,701,000 |
| Current Liabilities | $223,228,000 | $756,394,000 | $179,115,000 | $158,777,000 |
| Current Deferred Liabilities | $15,948,000 | $14,225,000 | $16,224,000 | $18,028,000 |
| Payables And Accrued Expenses | $195,621,000 | $176,100,000 | $154,569,000 | $140,749,000 |
| Payables | $122,558,000 | $105,118,000 | $94,391,000 | $85,197,000 |
| Other Payable | $327,000 | $32,000 | - | - |
| Accounts Payable | $122,231,000 | $105,086,000 | $94,391,000 | $85,197,000 |
| Other Non Current Liabilities | - | $18,000 | $18,000 | $148,000 |
| Non Current Deferred Liabilities | - | - | $0 | $2,878,000 |
| Equity | ||||
| Common Stock Equity | $340,466,000 | $360,179,000 | $362,496,000 | $441,170,000 |
| Total Equity Gross Minority Interest | $340,466,000 | $360,179,000 | $362,496,000 | $441,170,000 |
| Stockholders Equity | $340,466,000 | $360,179,000 | $362,496,000 | $441,170,000 |
| Gains Losses Not Affecting Retained Earnings | $-3,441,000 | $-5,500,000 | $-5,469,000 | $-2,433,000 |
| Other Equity Adjustments | $-3,441,000 | $-5,500,000 | $-5,469,000 | $-2,433,000 |
| Retained Earnings | $-1,290,357,000 | $-1,154,130,000 | $-985,503,000 | $-778,460,000 |
| Other | ||||
| Ordinary Shares Number | $112,492,667 | $108,516,819 | $107,075,754 | $105,049,411 |
| Share Issued | $112,492,667 | $108,516,819 | $107,075,754 | $105,049,411 |
| Tangible Book Value | $340,466,000 | $360,179,000 | $362,496,000 | $441,170,000 |
| Invested Capital | $535,513,000 | $1,015,639,000 | $931,318,000 | $1,006,679,000 |
| Working Capital | $423,503,000 | $350,181,000 | $855,294,000 | $952,752,000 |
| Capital Lease Obligations | $53,306,000 | $27,880,000 | $35,742,000 | $18,762,000 |
| Total Capitalization | $535,513,000 | $457,479,000 | $931,318,000 | $1,006,679,000 |
| Additional Paid In Capital | $1,634,264,000 | $1,519,809,000 | $1,353,468,000 | $1,222,063,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Employee Benefits | $3,938,000 | $6,940,000 | $8,258,000 | $4,404,000 |
| Long Term Capital Lease Obligation | $41,647,000 | $19,971,000 | $27,420,000 | $18,762,000 |
| Current Deferred Revenue | $15,948,000 | $14,225,000 | $16,224,000 | $18,028,000 |
| Current Capital Lease Obligation | $11,659,000 | $7,909,000 | $8,322,000 | - |
| Current Accrued Expenses | $73,063,000 | $70,982,000 | $60,178,000 | $55,552,000 |
| Net PPE | $146,999,000 | $119,591,000 | $97,698,000 | $68,958,000 |
| Accumulated Depreciation | $-69,259,000 | $-58,414,000 | $-54,813,000 | $-47,643,000 |
| Gross PPE | $216,258,000 | $178,005,000 | $152,511,000 | $116,601,000 |
| Leases | $13,727,000 | $12,132,000 | $11,696,000 | $9,346,000 |
| Other Properties | $115,820,000 | $84,491,000 | $80,713,000 | $63,836,000 |
| Machinery Furniture Equipment | $51,758,000 | $46,850,000 | $35,406,000 | $27,431,000 |
| Land And Improvements | $34,953,000 | $34,532,000 | $24,696,000 | $15,988,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $29,078,000 | $23,113,000 | $18,091,000 | $15,741,000 |
| Work In Process | $7,500,000 | $7,969,000 | $9,796,000 | $9,321,000 |
| Raw Materials | $4,533,000 | $4,004,000 | $10,265,000 | $4,314,000 |
| Other Short Term Investments | $354,126,000 | $796,106,000 | $669,795,000 | $854,099,000 |
| Treasury Shares Number | - | - | $0 | - |
| Non Current Deferred Revenue | - | - | $0 | $2,878,000 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-75,679,000 | $-69,224,000 | $-100,429,000 | $9,430,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-49,031,000 | $-26,369,000 | $-73,336,000 | $30,788,000 |
| Cash Flow From Continuing Operating Activities | $-49,031,000 | $-26,369,000 | $-73,336,000 | $30,788,000 |
| Operating Gains Losses | $1,251,000 | $-227,000 | $161,000 | $-3,256,000 |
| Investing Activities | ||||
| Capital Expenditure | $-26,648,000 | $-42,855,000 | $-27,093,000 | $-21,358,000 |
| Investing Cash Flow | $437,276,000 | $-140,242,000 | $184,148,000 | $-139,957,000 |
| Cash Flow From Continuing Investing Activities | $437,276,000 | $-140,242,000 | $184,148,000 | $-139,957,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $3,656,000 | $4,150,000 | $4,416,000 | $5,224,000 |
| Financing Cash Flow | $-451,343,000 | $90,315,000 | $15,787,000 | $15,491,000 |
| Cash Flow From Continuing Financing Activities | $-451,343,000 | $90,315,000 | $15,787,000 | $15,491,000 |
| Net Other Financing Charges | $-146,000 | - | - | - |
| Net Common Stock Issuance | $3,656,000 | $4,150,000 | $4,416,000 | $5,224,000 |
| Common Stock Issuance | $3,656,000 | $4,150,000 | $4,416,000 | $5,224,000 |
| Other | ||||
| Repayment Of Debt | $-560,945,000 | $-12,913,000 | $-10,000 | $-28,000 |
| Issuance Of Debt | $99,979,000 | $96,922,000 | $0 | $0 |
| Interest Paid Supplemental Data | $13,406,000 | $7,714,000 | $6,000 | $41,000 |
| Income Tax Paid Supplemental Data | $30,673,000 | $23,463,000 | $13,665,000 | $5,480,000 |
| End Cash Position | $103,390,000 | $166,094,000 | $242,564,000 | $115,834,000 |
| Beginning Cash Position | $166,094,000 | $242,564,000 | $115,834,000 | $209,609,000 |
| Effect Of Exchange Rate Changes | $394,000 | $-174,000 | $131,000 | $-97,000 |
| Changes In Cash | $-63,098,000 | $-76,296,000 | $126,599,000 | $-93,678,000 |
| Proceeds From Stock Option Exercised | $6,113,000 | $2,156,000 | $11,381,000 | $10,295,000 |
| Net Issuance Payments Of Debt | $-460,966,000 | $84,009,000 | $-10,000 | $-28,000 |
| Net Long Term Debt Issuance | $-460,966,000 | $84,009,000 | $-10,000 | $-28,000 |
| Long Term Debt Payments | $-560,945,000 | $-12,913,000 | $-10,000 | $-28,000 |
| Long Term Debt Issuance | $99,979,000 | $96,922,000 | $0 | $0 |
| Net Investment Purchase And Sale | $463,924,000 | $-97,387,000 | $211,241,000 | $-118,599,000 |
| Sale Of Investment | $1,285,000,000 | $778,000,000 | $1,214,982,000 | $1,179,289,000 |
| Purchase Of Investment | $-821,076,000 | $-875,387,000 | $-1,003,741,000 | $-1,297,888,000 |
| Net PPE Purchase And Sale | $-26,648,000 | $-42,855,000 | $-27,093,000 | $-21,358,000 |
| Purchase Of PPE | $-26,648,000 | $-42,855,000 | $-27,093,000 | $-21,358,000 |
| Change In Working Capital | $-20,075,000 | $-3,649,000 | $29,655,000 | $11,796,000 |
| Change In Other Current Liabilities | $-5,274,000 | $-6,360,000 | $-9,781,000 | $-7,773,000 |
| Change In Other Current Assets | $10,847,000 | $7,395,000 | $4,072,000 | $7,107,000 |
| Change In Payables And Accrued Expense | $18,958,000 | $19,106,000 | $14,869,000 | $14,257,000 |
| Change In Inventory | $-5,668,000 | $2,568,000 | $-8,919,000 | $-4,342,000 |
| Change In Receivables | $-38,938,000 | $-26,358,000 | $29,414,000 | $2,547,000 |
| Changes In Account Receivables | $-38,938,000 | $-26,358,000 | $29,414,000 | $2,547,000 |
| Other Non Cash Items | $4,949,000 | $-651,000 | $-95,000 | $-2,216,000 |
| Stock Based Compensation | $104,832,000 | $160,035,000 | $115,608,000 | $106,955,000 |
| Asset Impairment Charge | $4,851,000 | $1,159,000 | $493,000 | $955,000 |
| Amortization Of Securities | $-23,262,000 | $-25,644,000 | $-23,084,000 | $-1,536,000 |
| Depreciation Amortization Depletion | $14,650,000 | $11,235,000 | $10,969,000 | $10,624,000 |
| Depreciation And Amortization | $14,650,000 | $11,235,000 | $10,969,000 | $10,624,000 |
| Amortization Cash Flow | $1,519,000 | $1,369,000 | $1,274,000 | - |
| Amortization Of Intangibles | $1,519,000 | $1,369,000 | $1,274,000 | - |
| Depreciation | $13,131,000 | $9,866,000 | $9,695,000 | - |
| Net Foreign Currency Exchange Gain Loss | $1,251,000 | $-227,000 | $161,000 | $-3,256,000 |
| Net Income From Continuing Operations | $-136,227,000 | $-168,627,000 | $-207,043,000 | $-92,534,000 |
Fetched: 2026-06-17